Insider Selling: Quest Diagnostics SVP Catherine T. Doherty Unloads 25,000 Shares of Stock (DGX)
Quest Diagnostics (NYSE:DGX) SVP Catherine T. Doherty sold 25,000 shares of the company’s stock on the open market in a transaction dated Friday, August 8th. The shares were sold at an average price of $60.12, for a total transaction of $1,503,000.00. Following the completion of the sale, the senior vice president now directly owns 76,171 shares of the company’s stock, valued at approximately $4,579,401. The sale was disclosed in a document filed with the SEC, which is available at this link.
DGX has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Friday, August 1st. They now have a $64.00 price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Quest Diagnostics in a research note on Friday, July 25th. They now have a $65.00 price target on the stock, up previously from $60.00. Finally, analysts at Maxim Group raised their price target on shares of Quest Diagnostics from $68.00 to $74.00 in a research note on Friday, July 25th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $61.62.
Quest Diagnostics (NYSE:DGX) traded up 0.98% during mid-day trading on Monday, hitting $61.09. 988,701 shares of the company’s stock traded hands. Quest Diagnostics has a 52-week low of $50.46 and a 52-week high of $64.10. The stock has a 50-day moving average of $60.32 and a 200-day moving average of $57.29. The company has a market cap of $8.822 billion and a price-to-earnings ratio of 11.37.
Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, July 24th. The company reported $1.08 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.06 by $0.02. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter last year, the company posted $1.06 earnings per share. Quest Diagnostics’s revenue was up 4.8% compared to the same quarter last year. Analysts expect that Quest Diagnostics will post $4.05 EPS for the current fiscal year.
Quest Diagnostics Incorporated (NYSE:DGX) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.